Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital - FOX 18 Quad Cities News and Weather

Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Cardiva Medical, Inc.

SUNNYVALE, Calif., Aug. 19, 2014 /PRNewswire/ -- Cardiva Medical, Inc. announced today that it has closed the first two tranches of a $16.5 million Series 3 private equity financing and a $12.5 million senior secured facility with GE Capital. The Company will use the proceeds of the Series 3 private equity financing and debt facility to expand commercial efforts for its VASCADE® Vascular Closure System in the United States.

Investing in Series 3 private equity financing was a new investor, Canepa Advanced Healthcare Fund, L.P., who joined existing investors PTV Sciences, AmKey Ventures and TriVentures II Fund L.P.  Mr. Paul Enever from Canepa U.S., LLC, which serves as Investment Advisor to Canepa Advanced Healthcare Fund, L.P., has joined the Cardiva Board of Directors.

"We are extremely pleased that Canepa Advanced Healthcare, L.P. has joined Cardiva's current investors in this financing and that Paul Enever has joined our Board of Directors," said Charles Maroney, CEO. Maroney continued, "With the Series 3 equity financing and GE debt facility, Cardiva now has the financial resources to establish VASCADE as a leading extravascular closure technology which we believe can benefit both patients and healthcare providers in the United States by minimizing complications and associated costs and improving patient care when compared to conventional vascular closure devices."

"Cardiva's product platform offers the potential to transform the vascular closure market by improving both patient safety and comfort", said Paul Enever of Canepa U.S., LLC. Enever continued, "VASCADE leverages Cardiva's Catalyst® platform that has been utilized effectively in more than 400,000 procedures since its initial launch into the U.S. market in 2007". We are delighted to add Cardiva to our investment portfolio of emerging growth medical device companies that are focused on improving patient outcomes while reducing the cost of medical care."

About Cardiva Medical, Inc.
Cardiva Medical, Inc. is a medical device company that's focused on developing and commercializing innovative vascular closure technology designed to help the body heal itself following catheterization. The Company's products include VASCADE, a next generation extravascular closure system and Catalyst II and Catalyst III that are designed to aid manual compression. VASCADE was approved by the FDA in 2013 and approved for CE marking in 2012. Catalyst II and Catalyst III were cleared for marketing by the FDA in 2007 and 2009, respectively. For more information, go to http://www.cardivamedical.com/

VASCADE® and Cardiva Catalyst® are registered trademarks of Cardiva Medical, Inc.

Media Contact:
Malcolm Farnsworth
Chief Financial Officer
Cardiva Medical, Inc.
Phone: 650-388-8555
Mac_Farnsworth@cardivamedical.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow